Is low-frequency distribution of TGF-β genotype associated with increased risk for end-stage renal disease?

DNA and Cell Biology

Volumn 26, Issue 3, 2007, Pages 172-177

  Mittal, Rama Devi ^a   Manchanda, Parmeet Kaur ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; LEUCINE; MUTANT PROTEIN; PROLINE; TRANSFORMING GROWTH FACTOR BETA;

ADOLESCENT; ADULT; AGED; ARTICLE; CODON; CONTROLLED STUDY; DELETION MUTANT; DISEASE ASSOCIATION; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; GLOMERULONEPHRITIS; HAPLOTYPE; HUMAN; INTRON; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CODON; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; KIDNEY FAILURE, CHRONIC; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEPHRITIS; POLYMORPHISM, GENETIC; PROLINE; RISK; TRANSFORMING GROWTH FACTOR BETA;

EID: 34147181693     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2006.0520     Document Type: Article

References (34)

1. BAKER, A.J., MOONEY, A., HUGHES, J., LOMBARDI, D., JOHNSON, R.J., and SAVILL, J. (1994). Mesangial cell apoptosis: The major mechanism for resolution of glomerular hypercellularity in experimental mesangial proliferative nephritis. J. Clin. Invest. 94, 2105-2116.
2. BIDWELL, J., KEEN, L., GALLAGHER, G., KIMBERLY, R., HUIZINGA, T., MCDERMOTT, M.F., OKSENBERG, J., MCNICHOLL, J., POCIOT, F., HARDT, C., et al. (1999). Cytokine gene polymorphism in human disease: On-line databases. Genes Immun. 1, 3-19.
3. BORDER, W.A., and NOBLE, N.A. (1994). Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331, 1286-1292.
4. BORDER, W.A., and NOBLE, N.A. (1997). TGF-beta in kidney fibrosis: A target for gene therapy. Kidney Int. 51, 1388-1396.
5. BRANTON, M.H., and KOPP, J.B. (1999). TGF-beta and fibrosis. Microbes Infect. 1, 1349-1365.
6. BREZZI, B., LUPO, A., BRUGNARA, M., LIGABUE, G., MAGISTRONI, R., MARCANTONI, C., GOMEZ-LIRA, M., GAMBARO, G., TURCO, A., POLL, A., et al. (2002). TGF-beta1 COD 10 polymorphism is associated with progressive IgA nephropathy. J. Am. Soc. Nephrology 13, 130A.
7. COLL, E., CORMAND, B., CAMPOS, B., GONZALEZ-NUNEZ, D., INIGO, P., BOTEY, A., and POCH, E. (2004). Association of TGF-beta1 polymorphisms with chronic renal disease. Nephrology 17, 794-799.
8. COLLINS, A.J., KASISKE, B., HERZOG, C., CHEN, S.C., EVERSON, S., CONSTANTINI, E., GRIMM, R., MCBEAN, M., XUE, J., CHAVERS, B., et al. (2003). Excerpts from the United States Renal Data System 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am. J. Kidney Dis. 42 (6 Suppl 5), A5s-A7s.
9. DESCAMPS-LATSCHA, B., HERBELIN, A., NGUYEN, A.T., ROUX-LOMBARD, P., ZINGRAFF, J., MOYNOT, A., VERGER, C., DAHMANE, D., DE GROOTE, D., JUNGERS, P., et al. (1995). Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J. Immunol. 154, 882-892.
10. FIERLBECK, W., LIU, A., COYLE, R., and BALLERMANN, B.J. (2003). Endothelial cell apoptosis during glomerular capillary lumen formation in vivo. J. Am. Soc. Nephrol. 14, 1349-1354.
11. FREEDMAN, B.I., and BOWDEN, D.W. (1995). The role of genetic factors in the development of end-stage renal disease. Curr. Opin. Nephrol. Hypertens. 4, 230-234.
12. GIRNDT, M., SESTER, U., KAUL, H., and KOHLER, H. (1998). Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J. Am. Soc. Nephrol. 9, 1689-1696.
13. HANADA, T., and YOSHIMURA, A. (2002). Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev. 13, 413-421.
14. HOLWEG, C.T., BAAN, C.C., NIESTERS, H.G., VANTRIMPONT, P.J., MULDER, P.G., MAAT, A.P., WEIMAR, W., and BALK, A.H. (2001). TGF-beta1 gene polymorphisms in patients with end-stage heart failure. Heart Lung Transplant. 20, 979-984.
15. ISAKA, Y., FUJIWARA, Y., UEDA, N., KANEDA, Y., KAMADA, T., and IMAI, E. (1993). Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 92, 2597-2601.
16. KITAMURA, M., and FINE, L.G. (1999). The concept of glomerular self-defense. Kidney Int. 55, 1639-1671.
17. KOPP, J.B., FACTOR, V.M., MOZES, M., NAGY, P., SANDERSON, N., BOTTINGER, E.P., KLOTMAN, P.E., and THORGEIRSSON, S.S. (1996). Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab. Invest. 74, 991-1003.
18. KRAG, S., DANIELSEN, C.C., CARMELIET, P., NYENGAARD, J., and WOGENSEN, L. (2005). Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int. 68, 2651-2666.
19. LETTERIO, J.J., and ROBERTS, A.B. (1998). Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16, 137-161.
20. LIM, C.S., KIM, Y.S., CHAE, D.W., AHN, C., HAN, J.S., KIM, S., LEE, J.S., and KIM, I.S. (2005). Association of C-509T and T869C polymorphisms of transforming growth factor-beta1 gene with susceptibility to and progression of IgA nephropathy. Clin. Nephrol. 63, 61-67.
21. MA, L.J., JHA, S., LING, H., POZZI, A., LEDBETTER, S., and FOGO, A.B. (2004). Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int. 65, 106-115.
22. MILLER, S.A., DYKES, D.D., and POLESKY, H.F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
23. MURAKAMI, K., TAKEMURA, T., HINO, S., and YOSHIOKA, K. (1997). Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr. Nephrol. 11, 334-336.
24. NEGRI, A.L. (2004). Prevention of progressive fibrosis in chronic renal diseases: Antifibrotic agents. J. Nephrol. 17, 496-503.
25. NG, Y.Y., HOU, C.C., WANG, W., HUANG, X.R., and LAN, H.Y. (2005). Blockade of NFkappaB activation and renal inflammation by ultrasound-mediated gene transfer of Smad7 in rat remnant kidney. Kidney Int. Suppl. 94, S83-S91.
26. NORDFORS, L., LINDHOLM, B., and STENVINKEL, P. (2005). End-stage renal disease-Not an equal opportunity disease: The role of genetic polymorphisms. J. Intern. Med. 258, 1-12.
27. PATEL, P., VARGHESE, E., DING, G., FAN, S., KAPASI, A., REDDY, K., FRANKI, N., NAHAR, N., and SINGHAL, P. (2000). Transforming growth factor beta induces mesangial cell apoptosis through NO- and p53-dependent and -independent pathways. J. Investig. Med. 48, 403-410.
28. PERREY, C., TURNER, S.J., PRAVICA, V., HOWELL, W.M., and HUTCHINSON, IV. (1999). ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl. Immunol. 7, 127-128.
29. POCIOT, F., HANSEN, P.M., KARLSEN, A.E., LANGDAHL, B.L., JOHANNESEN, J., and NERUP, J. (1998). TGF-beta1gene mutations in insulin-dependent diabetes mellitus and diabetic nephropathy. J. Am. Soc. Nephrol. 9, 2302-2307.
30. RYSZ, J., BANACH, M., CIALKOWSKA-RYSZ, A., STOLAREK, R., BARYLSKI, M., DROZDZ, J., and OKONSKI, P. (2006). Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance hemodialysis. Cell. Mol. Immunol. 3, 151-154.
31. SENATORSKI, G., PACZEK, L., SULOWICZ, W., GRADOWSKA, L., and BARTLOMIEJCZYK, I. (1998). Urine activity of cathepsin B, collagenase and urine excretion of TGF-beta 1 and fibronectin in membranous glomerulonephritis. Res. Exp. Med. (Berl,) 198, 199-206.
32. WANG, W., HUANG, X.R., LI, A.G., LIU, F., LI, J.H., TRUONG, L.D., WANG, X.J., and LAN, H.Y. (2005a). Signaling mechanism of TGF-beta1 in prevention of renal inflammation: Role of Smad7. Am. Soc. Nephrol. 16, 1371-1383.
33. WANG, W., KOKA, V., and LAN, H.Y. (2005b). Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology (Carlton) 10, 48-56.
34. ZIYADEH, F.N., HOFFMAN, B.B., HAN, D.C., IGLESIAS-DE LA CRUZ, M.C., HONG, S.W., ISONO, M., CHEN, S., MCGOWAN, T.A., and SHARMA, K. (2000). Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97, 8015-8020.